drTarget portfolio target-disease associations for bioprocesses DrTarget’s AI-Powered Indication Expansion for Biological Processes

DrTarget’s AI-Powered Insights into Biological Processes

DrTarget has mapped 125 target proteins from PubChem screens across 24 bioprocesses, leveraging data from Open Targets. By applying machine learning models and AI-driven analytics, we identify novel molecular targets and bioprocess-level interactions that can drive breakthroughs in drug discovery, biotechnology, and synthetic biology.

Our AI-powered approach enables:

✔ Identification of critical molecular players in key bioprocesses
✔ Drug repurposing and bioengineering strategies
✔ Pathway analysis to optimize therapeutic intervention points

By integrating AI-based virtual screening, multi-source validation, and topological analysis, DrTarget provides deep insights into biological systems that can accelerate biopharma innovation and precision medicine applications.

Target-disease associations for bioprocesses.

Check best scored target-disease associations in table:

PubChemAssay	program	diseaseName	assayType	testedCompounds	activeCompounds	associationScore	numberOfEvidences
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	drug toxicity	targetBased	316642	617	0.0401653440373482	2
qHTS Assay for Inhibitors of DNA Polymerase Beta	POLB	aging	targetBased	334457	4509	0.0158227112874402	2
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	aging	targetBased	86095	1442	0.0831764875639315	11
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	aging	targetBased	86095	1151	0.0831764875639315	11
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	aging	targetBased	359207	1432	0.0908791622663231	3
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	aging	targetBased	363803	2412	0.04057105458318	3
qHTS for Inhibitors of TGF-b	TGFB1	aging	pathwayBased	403345	4970	0.0175621295617762	39
High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen	NFKB1	aging	pathwayBased	193265	3100	0.0337828780003565	49
uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay	NFKB1	aging	pathwayBased	359244	3094	0.0337828780003565	49
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	aging	targetBased	394050	3624	0.0811759183785126	4
Toxoplasma gondii inhibition HTS in the presence of IFN-y	IFNG	aging	targetBased	67275	2509	0.0120292260827054	29
Primary cell-based high throughput screening assay to measure STAT1 activation	STAT1 activation	aging	pathwayBased	195980	5134	0.0256134083373522	8
Primary cell-based high throughput screening assay to measure STAT1 inhibition	STAT1	aging	targetBased	195980	695	0.0256134083373522	8
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2)	NR5A2	aging	targetBased	363803	458	0.0328625542123758	2
FRET-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1)	HCRTR1	aging	targetBased	326024	5748	0.0109541847374586	2
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1)	HCRTR1	aging	targetBased	326024	1387	0.0109541847374586	2
Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-gamma1).	PLCG1	aging	targetBased	369953	3123	0.0141513252152147	2
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	aging	pathwayBased	362051	17187	0.0367125528123413	27
Activator for delta FosB/delta FosB homodimer Measured in Biochemical System Using Plate Reader - 2072-01_Activator_SinglePoint_HTS_Activity	FOSB	aging	targetBased	337391	3330	0.0113598952832904	3
Primary cell-based high-throughput screening for identification of compounds that inhibit/block calcium-activated chloride channels (TMEM16A)	ANO1_inhibitors	aging	targetBased	306502	3633	0.0158227112874402	2
Primary cell-based high-throughput screening for identification of compounds that activate/potentiate calcium-activated chloride channels (TMEM16A)	ANO1_activators	aging	targetBased	335180	1022	0.0158227112874402	2
E3 Ligase HTS_1536	MDM2	aging	targetBased	207811	220	0.0367844228220832	5
Luminescence cell-based high throughput primary assay to identify inhibitors of TEAD-YAP interaction.	YAP1	aging	targetBased	639428	9218	0.0225255002940769	8
qHTS assay for re-activators of p53 using a Luc reporter	TP53	aging	pathwayBased	321427	201	0.0112623070020131	40
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	aging	targetBased	54509	528	0.0112623070020131	40
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	aging	targetBased	54513	338	0.0112623070020131	40
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	aging	targetBased	125394	1890	0.0112623070020131	40
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	aging	targetBased	124022	1156	0.0112623070020131	40
Primary screen for compounds that activate Alzheimer's amyloid precursor	APP_inhibitors	aging	pathwayBased	193400	1987	0.0191472825380361	14
Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation	APP_inhibitors	aging	pathwayBased	193714	1590	0.0191472825380361	14
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP_inhibitors	aging	targetBased	404343	257	0.0191472825380361	14
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	aging	targetBased	356517	1139	0.0113279695487368	28
Primary qHTS assay for inhibitors of alpha-synuclein gene (SNCA) expression	SNCA	aging	pathwayBased	140118	236	0.0108556872327205	8
qHTS of alpha-syn Inhibitors	SNCA	aging	pathwayBased	368791	501	0.0108556872327205	8
human cGAS chemiluminescence screen	cGAS_inhibitors	aging	targetBased	281243	218	0.014889169549556	62
mouse cGAS chemiluminescence screen	cGAS_inhibitors	aging	targetBased	160326	237	0.014889169549556	62
mouse cGAS RapidFire screen	cGAS_inhibitors	aging	targetBased	123258	226	0.014889169549556	62
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	aging	targetBased	193542	587	0.0107513294645427	3
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	aging	pathwayBased	194666	1772	0.0217647930206423	8
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	aging	pathwayBased	194666	1722	0.0217647930206423	8
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	aging	targetBased	339297	1446	0.0198798167457582	2
Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3	HDAC3	aging	targetBased	318291	483	0.0268080005000792	8
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	aging	targetBased	324747	1043	0.0807363986205281	2
qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization	MAPT	aging	pathwayBased	271402	1048	0.0158768077520296	26
qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding	MAPT	aging	pathwayBased	267412	5703	0.0158768077520296	26
qHTS Assay for Tau Filament Binding	MAPT	aging	targetBased	69668	1391	0.0158768077520296	26
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	aging	pathwayBased	43989	342	0.0114363036193457	30
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	memory	targetBased	86095	1442	0.0411796204019277	3
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	memory	targetBased	86095	1151	0.0411796204019277	3
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	memory	targetBased	86095	1114	0.0401653440373482	2
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	memory	targetBased	339297	1446	0.0401653440373482	2
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	memory	targetBased	324747	1043	0.0401653440373482	2
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	insulin secretion	targetBased	405130	6428	0.405304835285968	2
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	insulin secretion	targetBased	373462	23	0.405304835285968	2
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	insulin secretion	targetBased	405130	6428	0.405304835285968	2
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	social behavior	targetBased	108286	1415	0.0198798167457582	2
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	social behavior	targetBased	324747	1043	0.405304835285968	2
HTS Assay for Activators of Cytochrome P450 2A9	CYP2C9_activators	trait in response to phenytoin	targetBased	95858	1368	0.456018653514943	3
CYP2C9 Assay	CYP2C9_inhibitors	trait in response to phenytoin	targetBased	95858	18730	0.456018653514943	3
High throughput screening of activators of transient receptor potential cation channel C6 (TRPC6)	TRPC6	trait in response to prednisolone	targetBased	305610	382	0.589325800565095	50
High throughput screening of inhibitors of transient receptor potential cation channel C6 (TRPC6)	TRPC6	trait in response to prednisolone	targetBased	305610	3253	0.589325800565095	50
FRET-based HTS for detection of RAD52 Inhibitors Measured in Biochemical System Using Plate Reader - 7018-01_Inhibitor_SinglePoint_HTS_Activity_Set2	RAD52	aging	targetBased	352074	1608	0.0248749681130703	1
qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).	FEN1_inhibitors	aging	targetBased	386270	1331	0.01299026008394	1
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	transport	targetBased	405130	6428	0.134831138064768	1
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	transport	targetBased	373462	23	0.134831138064768	1
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	transport	targetBased	405130	6428	0.134831138064768	1
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	protein localization	targetBased	405130	6428	0.134831138064768	1
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	protein localization	targetBased	373462	23	0.134831138064768	1
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	protein localization	targetBased	405130	6428	0.134831138064768	1
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	secretion by cell	targetBased	405130	6428	0.134831138064768	1
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	secretion by cell	targetBased	373462	23	0.134831138064768	1
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	secretion by cell	targetBased	405130	6428	0.134831138064768	1
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	establishment of protein localization	targetBased	405130	6428	0.134831138064768	1
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	establishment of protein localization	targetBased	373462	23	0.134831138064768	1
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	establishment of protein localization	targetBased	405130	6428	0.134831138064768	1
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	hormone secretion	targetBased	405130	6428	0.134831138064768	1
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	hormone secretion	targetBased	373462	23	0.134831138064768	1
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	hormone secretion	targetBased	405130	6428	0.134831138064768	1
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	establishment of localization	targetBased	405130	6428	0.134831138064768	1
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	establishment of localization	targetBased	373462	23	0.134831138064768	1
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	establishment of localization	targetBased	405130	6428	0.134831138064768	1
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	cellular localization	targetBased	405130	6428	0.134831138064768	1
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	cellular localization	targetBased	373462	23	0.134831138064768	1
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	cellular localization	targetBased	405130	6428	0.134831138064768	1
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	protein secretion	targetBased	405130	6428	0.134831138064768	1
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	protein secretion	targetBased	373462	23	0.134831138064768	1
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	protein secretion	targetBased	405130	6428	0.134831138064768	1
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	protein transport	targetBased	405130	6428	0.134831138064768	1
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	protein transport	targetBased	373462	23	0.134831138064768	1
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	protein transport	targetBased	405130	6428	0.134831138064768	1
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	reproductive process	targetBased	86095	1442	0.20856871651785	9
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	reproductive process	targetBased	86095	1151	0.20856871651785	9
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	reproductive process	targetBased	394050	3624	0.135819118375451	3
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	reproductive process	targetBased	335239	991	0.20395690667958	7
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	reproductive process	targetBased	335239	695	0.20395690667958	7
Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen	PTGER2	reproductive process	targetBased	250190	1304	0.169016008130225	2
Modulators of the EP2 prostaglandin E2 receptor - Primary Screening	PTGER2	reproductive process	targetBased	255537	2141	0.169016008130225	2
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	reproductive process	targetBased	86095	1114	0.13855015140156	2
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	reproductive process	targetBased	359518	300	0.168640350217418	1
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	reproductive process	targetBased	335652	1779	0.168640350217418	1
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	reproductive process	targetBased	362274	1056	0.168640350217418	1
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	reproductive process	targetBased	336308	6862	0.168640350217418	1
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	reproductive process	targetBased	357537	806	0.168640350217418	1
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	reproductive process	targetBased	339887	1178	0.168640350217418	1
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	reproductive process	targetBased	359207	1189	0.134831138064768	1
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	reproductive process	targetBased	63676	1938	0.134831138064768	1
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	reproductive process	targetBased	359207	316	0.134831138064768	1
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	reproductive process	targetBased	63656	2179	0.134831138064768	1
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	reproductive process	targetBased	359207	4555	0.134831138064768	1
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	reproductive process	targetBased	339297	1446	0.195327088343243	3
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	reproductive process	targetBased	324747	1043	0.204044958526296	4
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	reproductive process	targetBased	343468	734	0.102524557563347	2

Some of these associations have also gone through clinical trials, as those in the graph below.

Find clinical trials details in table. Use scroll bar or search funtion to select specific drugs, molecular targets or diseases.

BioAssay Name	program	gene	protName	diseaseName	molname	assayMode	clinicalPhase	clinicalStatus	studyStartDate	url	score	variantEffect	directionOnTrait	studyStopReason
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	memory	PROPRANOLOL	targetBased	1	Completed		https://clinicaltrials.gov/study/NCT00889096	0.1	LoF	protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	drug toxicity	ACETAMINOPHEN	targetBased	1	Recruiting	15/01/2024	https://clinicaltrials.gov/study/NCT06214468	0.1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	aging	ESTRADIOL	targetBased	2	Completed	01/12/2002	https://clinicaltrials.gov/study/NCT00220454	0.2	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	aging	ESTRADIOL	targetBased	2	Completed	01/12/2002	https://clinicaltrials.gov/study/NCT00220454	0.2	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	aging	ESMOLOL	targetBased		Completed	02/02/2022	https://clinicaltrials.gov/study/NCT04181606	0.05	LoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	aging	CHOLECALCIFEROL	targetBased	2	Unknown status	01/07/2014	https://clinicaltrials.gov/study/NCT02222649	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	aging	PSILOCYBINE	targetBased	1	Not yet recruiting	01/04/2025	https://clinicaltrials.gov/study/NCT06367738	0.1	GoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	aging	DASATINIB	targetBased	2	Active, not recruiting	16/12/2020	https://clinicaltrials.gov/study/NCT04946383	0.2	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	aging	DASATINIB	targetBased	1	Completed	20/05/2022	https://clinicaltrials.gov/study/NCT05422885	0.1	LoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	aging	OXYTOCIN	targetBased	2	Withdrawn	01/01/2019	https://clinicaltrials.gov/study/NCT02409862	0.2	GoF	protect	Technical issues preventing recruitment.
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	memory	OXYTOCIN	targetBased	1	Completed	18/09/2016	https://clinicaltrials.gov/study/NCT04330677	0.1	GoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	social behavior	OXYTOCIN	targetBased	4	Completed	01/01/2016	https://clinicaltrials.gov/study/NCT03010670	1	GoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	social behavior	METHAMPHETAMINE	targetBased		Completed	11/05/2022	https://clinicaltrials.gov/study/NCT05379959	0.05	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	memory	ESTROGENS, CONJUGATED	targetBased	1	Completed	18/09/2016	https://clinicaltrials.gov/study/NCT04330677	0.1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	memory	ESTROGENS, CONJUGATED	targetBased	1	Completed	18/09/2016	https://clinicaltrials.gov/study/NCT04330677	0.1	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	memory	ESTROGENS, CONJUGATED	targetBased	1	Completed	18/09/2016	https://clinicaltrials.gov/study/NCT04330677	0.1	GoF	protect
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	insulin secretion	AVEXITIDE	targetBased	4	Completed	01/07/2018	https://clinicaltrials.gov/study/NCT02844907	1	LoF	protect
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	insulin secretion	AVEXITIDE	targetBased	4	Completed	01/07/2018	https://clinicaltrials.gov/study/NCT02844907	1	LoF	protect
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	insulin secretion	AVEXITIDE	targetBased	4	Completed	01/07/2018	https://clinicaltrials.gov/study/NCT02844907	1	LoF	protect

BioAssay Name	program	gene	protName	diseaseName	molname	assayMode	clinicalPhase	clinicalStatus	studyStartDate	url	score	variantEffect	directionOnTrait	studyStopReason
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	memory	PROPRANOLOL	targetBased	1	Completed		https://clinicaltrials.gov/study/NCT00889096	0.1	LoF	protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	drug toxicity	ACETAMINOPHEN	targetBased	1	Recruiting	15/01/2024	https://clinicaltrials.gov/study/NCT06214468	0.1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	aging	ESTRADIOL	targetBased	2	Completed	01/12/2002	https://clinicaltrials.gov/study/NCT00220454	0.2	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	aging	ESTRADIOL	targetBased	2	Completed	01/12/2002	https://clinicaltrials.gov/study/NCT00220454	0.2	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	aging	ESMOLOL	targetBased		Completed	02/02/2022	https://clinicaltrials.gov/study/NCT04181606	0.05	LoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	aging	CHOLECALCIFEROL	targetBased	2	Unknown status	01/07/2014	https://clinicaltrials.gov/study/NCT02222649	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	aging	PSILOCYBINE	targetBased	1	Not yet recruiting	01/04/2025	https://clinicaltrials.gov/study/NCT06367738	0.1	GoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	aging	DASATINIB	targetBased	2	Active, not recruiting	16/12/2020	https://clinicaltrials.gov/study/NCT04946383	0.2	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	aging	DASATINIB	targetBased	1	Completed	20/05/2022	https://clinicaltrials.gov/study/NCT05422885	0.1	LoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	aging	OXYTOCIN	targetBased	2	Withdrawn	01/01/2019	https://clinicaltrials.gov/study/NCT02409862	0.2	GoF	protect	Technical issues preventing recruitment.
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	memory	OXYTOCIN	targetBased	1	Completed	18/09/2016	https://clinicaltrials.gov/study/NCT04330677	0.1	GoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	social behavior	OXYTOCIN	targetBased	4	Completed	01/01/2016	https://clinicaltrials.gov/study/NCT03010670	1	GoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	social behavior	METHAMPHETAMINE	targetBased		Completed	11/05/2022	https://clinicaltrials.gov/study/NCT05379959	0.05	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	memory	ESTROGENS, CONJUGATED	targetBased	1	Completed	18/09/2016	https://clinicaltrials.gov/study/NCT04330677	0.1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	memory	ESTROGENS, CONJUGATED	targetBased	1	Completed	18/09/2016	https://clinicaltrials.gov/study/NCT04330677	0.1	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	memory	ESTROGENS, CONJUGATED	targetBased	1	Completed	18/09/2016	https://clinicaltrials.gov/study/NCT04330677	0.1	GoF	protect
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	insulin secretion	AVEXITIDE	targetBased	4	Completed	01/07/2018	https://clinicaltrials.gov/study/NCT02844907	1	LoF	protect
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	insulin secretion	AVEXITIDE	targetBased	4	Completed	01/07/2018	https://clinicaltrials.gov/study/NCT02844907	1	LoF	protect
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	insulin secretion	AVEXITIDE	targetBased	4	Completed	01/07/2018	https://clinicaltrials.gov/study/NCT02844907	1	LoF	protect

Partner with DrTarget for AI-Optimized Screening

We welcome collaborations with biotech companies, research institutions, and pharmaceutical partners looking to leverage AI for drug discovery. Get in touch to explore custom screening solutions and accelerate your research.

drTarget portfolio target-disease associations for bioprocesses

DrTarget’s AI-Powered Insights into Biological Processes

Our AI-powered approach enables:

✔ Identification of critical molecular players in key bioprocesses✔ Drug repurposing and bioengineering strategies✔ Pathway analysis to optimize therapeutic intervention points

By integrating AI-based virtual screening, multi-source validation, and topological analysis, DrTarget provides deep insights into biological systems that can accelerate biopharma innovation and precision medicine applications.

Check best scored target-disease associations in table:

Some of these associations have also gone through clinical trials, as those in the graph below.

Partner with DrTarget for AI-Optimized Screening

We welcome collaborations with biotech companies, research institutions, and pharmaceutical partners looking to leverage AI for drug discovery. Get in touch to explore custom screening solutions and accelerate your research.

✔ Identification of critical molecular players in key bioprocesses
✔ Drug repurposing and bioengineering strategies
✔ Pathway analysis to optimize therapeutic intervention points